Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

Editas Medicine and Genevant Sciences will collaborate to ... was one concerning Casgevy (exagamglogene autotemcel), the ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Editas Medicine, Inc. struck a deal on October 3 ... Better, the U.S. FDA has already approved gene therapy treatments for forms of cancer, muscular atrophy, hemophilia and sickle cell anemia. B ...

ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...

Gene therapy companies, like Editas, carry additional risks due to the therapies being a new class in the field of medicine and its complex regulatory environment. Even if a gene therapy receives ...

Editas remains focused on getting its own gene therapy, reni-cel, ready for regulators—with readouts from studies in SCD and transfusion-dependent beta thalassemia due by the end of the year.